Form 4: Haemonetics CFO James D'Arecca Reports Equity Transactions

Haemonetics Corporation EVP and CFO James D'Arecca reported the vesting of restricted stock units and associated tax withholding.

Summary

• James D'Arecca, EVP and CFO of Haemonetics Corporation, engaged in equity transactions on May 15, 2026.
• The reporting person acquired 29,312 restricted stock units (RSUs) under the 2019 Long-Term Incentive Compensation Plan.
• A total of 2,505 shares were withheld by the company to satisfy tax obligations related to the vesting of previously reported RSUs.
• Following these transactions, the reporting person holds a total of 54,444 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding executive compensation and does not signal a change in company outlook.

Positives

• The acquisition of 29,312 RSUs indicates long-term incentive alignment between the CFO and the company's performance.

Negatives

• The transaction involved a tax-related withholding of 2,505 shares, which is a standard administrative procedure but reduces the net share increase.

Risks

• The value of the RSUs is subject to future market performance of Haemonetics common stock.

Future Outlook

The RSUs granted vest in three annual installments: 40% on the first anniversary, 40% on the second, and 20% on the third.

Management Comments

• The RSUs represent a contingent right to receive one share of common stock per unit upon vesting.

Industry Context

StockSavvy.ai notes that executive equity grants are standard practice in the medical device sector to ensure leadership retention and alignment with shareholder interests.

Comparison to Industry Standards

• The use of multi-year vesting schedules for RSUs is consistent with standard executive compensation practices among mid-cap medical technology firms.
• Tax withholding via share reduction is a standard industry practice for equity-based compensation.

Stakeholder Impact

• Shareholders should note the dilution impact of new RSU grants, though these are typically accounted for in existing compensation plans.

Next Steps

• Vesting of the newly granted 29,312 RSUs according to the three-year schedule.

Key Dates

Keywords

Haemonetics, HAE, Form 4, Insider Trading, CFO, Equity Compensation, Restricted Stock Units